|
|
 |
|
Viewing report
|
|
|
|
COPD Drug Discovery: How New Generation Therapies Seek to Target Underlying Disease
Drug and Market Development Publishing, June 2006, Pages: 140
Chronic Obstructive Pulmonary Disease (COPD) has been a much neglected area in drug development for several decades but now is the fifth leading cause of death worldwide.
Widely recognized as self-inflicted by smoking, COPD has often had low priority in respiratory programs. It is now realized that at least 600 million people, worldwide, suffer from COPD-numbers indicative of epidemic proportions. Governments, healthcare workers and pharmaceutical companies have recently prioritized and raised awareness of this disease area as one of major unmet medical need. Indicative of prioritization of this disease is the widespread occurrence of COPD-specific drug discovery in respiratory R&D in pharmaceutical companies. It is evident that a paradigm shift is taking place in COPD drug discovery. Rather than the traditional approach of symptom relief; new generation pharmaceuticals are beginning to target underlying disease.
“COPD Drug Discovery: How New Generation Therapies Seek to Target Underlying Disease” market analysis report seeks to provide background information on COPD, relevant drug targets, drug discovery strategies and associated therapeutics in current clinical development. This report examines the major classes of COPD therapeutics and discusses the approved and emerging COPD therapeutics. Buy this report to explore the therapeutic and market potential of select therapeutics and new research data compiled from an up-to-date survey.
Key Reasons to Purchase
- Determine what is new in COPD-related drug discovery by review of clinical developments in current pharmaceutical pipelines
- Get an up-to-date perspective on wider industry developments related to COPD drug discovery by survey of relevant industry news
- Assess the therapeutic potential of emerging COPD therapeutics by understanding underlying drug targets and technology that is facilitated drug development and delivery
- Assess the market opportunities associated with COPD drug discovery from maps of the current market landscape, evaluation of market needs and consideration of the direction of early stage drug discovery
- Gain broader insight into current COPD treatment by consideration of non-pharmacological approaches
- Look inside 20 companies involved in COPD drug discovery, including their product pipelines, financial standing, partnerships & alliances, and more
- Obtain a current industry snapshot of COPD drug discovery from a short survey conducted in parallel with the writing of this report
- Gain insight into current challenges in COPD drug discovery through in-depth interviews with industry experts
Questions Answered
- Who is currently developing COPD therapeutics?
- What are the key drug targets that underlie such developments and which have major therapeutic and commercial potential?
- How is COPD treatment changing?
- What are the relative merits of approved COPD therapeutics?
- What are the competitive advantages of new-generation COPD drugs?
- Where are the current challenges in COPD drug development?
- How can COPD treatment be 'tailor-made'
- Where are the opportunities relating to COPD drug development?
- What are the future prospects for COPD therapeutics?
Market Opportunities
- Invest in basic research to uncover the molecular pathways associated with development of COPD and to uncover new drug targets
- Develop model systems for clinical investigation of COPD to accelerate drug development
- Develop technology platforms for development of targeted COPD therapeutics with reduced side effects
- Develop diagnostic tests for use with new therapies so that treatment regimes can be tailored for a specific patient
- Investigate the mechanisms involved in the inflammatory response associated with COPD to allow drug targeting of COPD-specific inflammation
- Investigate the mechanisms involved in the COPD-specific immune response associated with COPD to allow drug targeting of the COPD-specific immune response
- Develop COPD-specific therapeutics that target the systemic element of the disease
About the Author
Dr Catherine M. Thomson has worked in medical and biological research for twenty years. Research areas span cancer, neurodegenerative disease, and arthritis and rheumatism. A particular emphasis has been the development of visible molecular tags or indicator technology for medical research. Her PhD was obtained at the University of Wales, College of Medicine, Cardiff, South Wales, UK and her first degree in Molecular Biology from Glasgow University, Scotland, UK. Over the past five years Dr Thomson has worked at, and for, the Center for Research and Education in Bioluminescence and Biotechnology (CREBB), Rutgers University, NJ, USA in roles of research, instruction and consulting. Dr Thomson currently works as a consultant and analyst for the pharmaceutical and biotechnology industries. Recently, Dr Thomson authored “Breast Cancer Therapeutics: How Innovation is Shaping Future Therapies,” “Phosphodiesterases: A Drug Target Family with Broad Therapeutic Impact,” and co-authored ‘Fluorescent Proteins: Technologies, Applications, and Opportunities for Drug Discovery,’ and ‘A Guide to Green Fluorescent Protein: Applications in Cell Biology and Drug Discovery’.
Product samples
AstraZeneca Plc
COPD Drug Discovery Summary
COPD in the Respiratory Market
Customers who bought this item also bought
Treating COPD Comorbidities: A Market Opportunity for Systemic Anti-Inflammatory Agents?
Commercial Insight: Asthma and Copd - Combinations breathe life into the asthma and Copd markets
Pipeline Insight: Asthma/COPD - Targeted Therapies on the Horizon
Commercial Insight: Asthma & COPD - Combination products still have blockbuster potential
Asthma And COPD - Get Smart
COPD - Another Reason to Quit
Asthma and COPD Drug Discoveries: What the Future Holds
Chronic Obstructive Pulmonary Disease (Copd) Update - Considerable Unmet Needs Invigorate Interest in the Copd Market
Strategic Perspectives 2001: The Copd Market - Gaining A New Identity
U.S. COPD Market: Therapeutic Overview and Patient Outlook
U.S. COPD Market - Therapeutic Overview and Patient Outlook
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011
|
|
|
|
